Top Page
VSee Health
(NASDAQ:VSEE)
VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)
VSee Health Business Overview & Revenue Model
VSee Health Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.42M | 5.77M | 6.38M | 7.34M | 6.80M |
| Gross Profit | 7.18M | 3.83M | 4.84M | 5.92M | 5.46M |
| EBITDA | -3.36M | -1.79M | 0.00 | 0.00 | 0.00 |
| Net Income | -57.70M | -3.76M | -836.21K | 475.90K | 258.88K |
Balance Sheet | |||||
| Total Assets | 19.99M | 830.79K | 2.61M | 1.94M | 2.73M |
| Cash, Cash Equivalents and Short-Term Investments | 326.12K | 118.73K | 230.66K | 346.44K | 775.24K |
| Total Debt | 9.55M | 543.00K | 517.13K | 0.00 | 133.08K |
| Total Liabilities | 20.01M | 4.24M | 2.61M | 1.01M | 2.11M |
| Stockholders Equity | -18.49K | -3.09M | 360.72K | 1.20M | 614.49K |
Cash Flow | |||||
| Free Cash Flow | -5.84M | -636.93K | -1.45M | -459.80K | 789.12K |
| Operating Cash Flow | -5.79M | -632.60K | -1.45M | -459.80K | 789.12K |
| Investing Cash Flow | -26.14K | -4.33K | 110.12M | -116.73M | 0.00 |
| Financing Cash Flow | 6.02M | 525.00K | 710.00K | 31.00K | -83.67K |
VSee Health Technical Analysis
VSee Health Peers Comparison
VSee Health Corporate Events
On October 29, 2025, VSee Health, Inc. entered into a warrant exchange agreement with an institutional investor, resulting in the exercise of approximately 130,000 outstanding warrants for cash and the exchange of 2,250,000 warrants for 2,175,000 shares of common stock. This agreement, governed by the Securities Act of 1933, imposes restrictions on the company’s ability to issue new stock or equivalents and undertake certain corporate actions for ten days following the agreement, potentially impacting its market strategy and stakeholder interests.
The most recent analyst rating on (VSEE) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
VSee Health, Inc. has announced that its 2025 annual meeting of stockholders will be held on December 15, 2025, with November 20, 2025, set as the record date for determining eligible stockholders. The company has outlined the deadlines and requirements for stockholder proposals and proxy solicitations, emphasizing the importance of meeting the November 7, 2025, deadline for inclusion in the proxy materials and compliance with SEC regulations.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On October 21, 2025, VSee Health, Inc. amended its senior secured convertible promissory note, originally issued on September 30, 2024, to redefine the ‘Conversion Price’ to $0.75. This amendment maintains all other terms of the note, potentially impacting the company’s financial strategy and investor relations.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On October 20, 2025, VSee Health, Inc. entered into a note purchase agreement with an accredited institutional investor, issuing a secured note worth $133,333.33 at a purchase price of $120,000. The note, which bears a 5% annual interest rate and matures on May 20, 2026, includes standard default provisions and restrictions on variable rate transactions and exchange transactions involving the company’s debt or securities. Additionally, on the same date, VSee Health amended previous security agreements to ensure the note is fully secured by the company’s assets. On October 18, 2025, the company terminated an Equity Purchase Agreement from November 21, 2023, with another accredited institutional investor.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On October 9, 2025, VSee Health, Inc. entered into a note purchase agreement with an accredited institutional investor, issuing a secured note for $133,333.33 with a purchase price of $120,000, bearing an interest rate of 5% per annum and maturing on May 8, 2026. The agreement includes restrictions on variable rate transactions and mandates equal terms for future debt holders, while an amendment agreement ensures the note is fully secured by the company’s assets, potentially strengthening VSee Health’s financial stability and market position.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On August 5, 2025, VSee Health, Inc. received a notice from Nasdaq indicating a potential suspension of its stock and warrants due to non-compliance with listing rules, including failure to timely file financial reports and insufficient stockholders’ equity. The company is appealing the decision and plans to address these deficiencies in a hearing scheduled for September 9, 2025. If the appeal is unsuccessful, VSee Health’s securities may be delisted, potentially limiting market access and affecting trading prices.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
VSee Health, Inc. received a notice from Nasdaq on August 20, 2025, for non-compliance with listing rules due to delayed filing of required reports with the SEC. The company is scheduled for a hearing on September 9, 2025, to appeal the decision to delist its stock and warrants from Nasdaq, with trading expected to move to OTC Markets if delisting proceeds. The potential delisting could limit market accessibility for shareholders and affect stock prices.
The most recent analyst rating on (VSEE) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.